Eun Jin, Ahn Stephen, Lee Min Ho, Choi Jin-Gyu, Park Jae-Sung, Cho Chul Bum, Kim Young Il
Department of Neurosurgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Korean Neurosurg Soc. 2023 Nov;66(6):726-734. doi: 10.3340/jkns.2023.0115. Epub 2023 Aug 8.
Chronic subdural hematoma (CSDH) patients using antithrombotic agents (AT) at high risk for cardiovascular disease are increasing. The authors aimed to analyze the factors influencing outcome by targeting patients using AT and to establish a desirable treatment strategy.
A retrospective analysis was performed on data from 462 patients who underwent burr hole trephination (BHT) surgery for CSDH at five hospitals from March 2010 to June 2021. Outcomes included incidence of postoperative acute bleeding, recurrence rate, and morbidity or mortality rate. Patients were divided into the following four groups based on their history of AT use : no AT. Only antiplatelet agents (AP), only anticoagulants (AC), both of AP and AC. In addition, a concurrent literature review was conducted alongside our cohort study.
Of 462 patients, 119 (119/462, 25.76%) were using AT. AP prescription did not significantly delay surgery (p=0.318), but AC prescription led to a significant increase in the time interval from admission to operation (p=0.048). After BHT, AP or AC intake significantly increased the period required for an in-dwelling drain (p=0.026 and p=0.037). The use of AC was significantly related to acute bleeding (p=0.044), while the use of AP was not (p=0.808). Use of AP or AC had no significant effect on CSDH recurrence (p=0.517 and p=1.000) or reoperation (p=0.924 and p=1.000). Morbidity was not statistically correlated with use of either AP or AC (p=0.795 and p=0.557, respectively), and there was no significant correlation with mortality for use of these medications (p=0.470 and p=1.000).
Elderly CSDH patients may benefit from maintenance of AT therapy during BHT due to reduced thromboembolic risk. However, the use of AC necessitates individualized due to potential postoperative bleeding. Careful post-operative monitoring could mitigate prognosis and recurrence impacts.
使用抗血栓药物(AT)且心血管疾病风险较高的慢性硬膜下血肿(CSDH)患者数量正在增加。作者旨在通过针对使用AT的患者分析影响预后的因素,并制定理想的治疗策略。
对2010年3月至2021年6月期间在五家医院因CSDH接受钻孔引流术(BHT)的462例患者的数据进行回顾性分析。结局指标包括术后急性出血发生率、复发率以及发病率或死亡率。根据患者使用AT的病史将其分为以下四组:未使用AT、仅使用抗血小板药物(AP)、仅使用抗凝剂(AC)、同时使用AP和AC。此外,在我们的队列研究同时进行了文献综述。
462例患者中,119例(119/462,25.76%)正在使用AT。AP处方并未显著延迟手术(p=0.318),但AC处方导致从入院到手术的时间间隔显著增加(p=0.048)。BHT术后,服用AP或AC显著增加了留置引流管所需的时间(p=0.026和p=0.037)。AC的使用与急性出血显著相关(p=0.044),而AP的使用则无此关联(p=0.808)。使用AP或AC对CSDH复发(p=0.517和p=1.000)或再次手术(p=0.924和p=1.000)无显著影响。发病率与使用AP或AC均无统计学相关性(分别为p=0.795和p=0.557),且这些药物的使用与死亡率无显著相关性(p=0.470和p=1.000)。
老年CSDH患者在BHT期间维持AT治疗可能因降低血栓栓塞风险而获益。然而,由于潜在的术后出血,AC的使用需要个体化。术后仔细监测可减轻对预后和复发的影响。